FDA-Approved Ruxolitinib in Patients with Myelofibrosis: the Stanford Experience

被引：0

作者：

Nguyen, Huong ^{[1
]}

Anh Pham ^{[1
]}

Perkins, Cecelia ^{[1
]}

Linder, Andrea ^{[1
]}

Fechter, Lenn ^{[1
]}

Gotlib, Jason ^{[1
]}

机构：

[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1747

引用

页数：2

共 50 条

[1] Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
Mascarenhas, John
Hoffman, Ronald
CLINICAL CANCER RESEARCH, 2012, 18 (11) : 3008 - 3014
[2] FDA-APPROVED INDICATIONS
ANDERSON, DA
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1984, 41 (11): : 2328 - 2328
[3] FDA-Approved Antibacterials and Echinocandins
Al Musaimi, Othman
ANTIBIOTICS-BASEL, 2025, 14 (02):
[4] Recent changes to FDA-approved labelling
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (17) : 1766 - 1766
[5] Target selection for FDA-approved medicines
Kinch, Michael S.
Hoyer, Denton
Patridge, Eric
Plummer, Mark
DRUG DISCOVERY TODAY, 2015, 20 (07) : 784 - 789
[6] Recent changes to FDA-approved labeling
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (09) : 828 - 828
[7] Recent changes to FDA-approved labeling
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (12) : 1242 - +
[8] Recent changes to FDA-approved labeling
不详
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (08) : 742 - 742
[9] Safety of FDA-Approved drugs - Reply
Friedman, MA
Woodcock, J
Lumpkin, MM
Shuren, JE
Hass, AE
Thompson, LJ
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (24): : 2297 - 2298
[10] Usability of FDA-Approved Medication Guides
Wolf, Michael S.
King, Jennifer
Wilson, Elizabeth A. H.
Curtis, Laura M.
Bailey, Stacy Cooper
Duhig, James
Russell, Allison
Bergeron, Ashley
Daly, Amanda
Parker, Ruth M.
Davis, Terry C.
Shrank, William H.
Lambert, Bruce
JOURNAL OF GENERAL INTERNAL MEDICINE, 2012, 27 (12) : 1714 - 1720

← 1 2 3 4 5 →